Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from Managing Editor Angela Maas.
View a sample and get more information
April 2016

Recent Stories

From Specialty Pharmacy News - In a little more than a year after the FDA approved the first biosimilar, Zarxio (filgrastim-sndz), reference drug Neupogen (filgrastim), the agency has approved a second drug that used the 351(k) approval pathway. On April 5, the FDA approved Celltrion, Inc.’s biosimilar Inflectra (infliximab-dyyb). The infusible monoclonal antibody is a biosimilar version of Janssen Biotech, Inc.’s Remicade (infliximab), which received its initial FDA approval in 1998. Read more

CMS’s recently proposed rule that would test different reimbursement tactics in Medicare… Read more

On March 8, CMS unveiled a proposed multipronged approach that would test… Read more

Aetna Inc. is continuing to broaden its oncology care management approach with… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

April 6, 2016
FDA Approves Second Biosimilar

The FDA approves Celltrion’s Inflectra for all indications of the reference product, Janssen Biotech’s Remicade; drug is second FDA-approved biosimilar, first monoclonal antibody

March 31, 2016
FDA Issues More Biosimilars Draft Guidance

FDA releases draft guidance on biosimilar products’ labeling, gives 60-day comment period

March 8, 2016
CMS Proposes Expanding Value-Based Approach to Medicare Part B

CMS proposed demo project for Medicare Part B includes changing ASP + 6% to ASP + 2.5% plus a $16.80 flat fee payment

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?